Indian Patents. 269467:HYDROXAMATE COMPOUNDS AS DEACETYLASE INHIBITORS

Title of Invention	HYDROXAMATE COMPOUNDS AS DEACETYLASE INHIBITORS
Abstract	The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having antiproliferative properties.

Full Text	DEACETYLASE INHIBITORS The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. The inventive compounds are useful as pharmaceuticals for the treatment of proliferative diseases. Background Reversible acetylation of histones is a major regulator of gene expression that acts by altering accessibility of transcription factors to DNA. In normal cells, histone deacetylase (HDA) and histone acetyltrasferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDA results in the accumulation of hyperacetylated histones, which results in a variety of cellular responses. Inhibitors of HDA have been studied for their therapeutic effects on cancer cells. For example, butyric acid and its derivatives, including sodium phenylbutyrate, have been reported to induce apoptosis in vitro in human colon carcinoma, leukemia and retinoblastoma cell lines. However, butyric acid and its derivatives are not useful phamnacological agents because they tend to be metabolized rapidly and have a very short half-life in vivo. Other inhibitors of HDA that have been widely studied for their anti-cancer activities are trichostatin A and trapoxin. Trichostatin A is an antifungal and antibiotic and is a reversible inhibitor of mammalian HDA. Trapoxin is a cyclic tetrapeptide, which is an irreversible inhibitor of mammalian HDA. Although trichostatin and trapoxin have been studied for their anti-cancer activities, the in vivo instability of the compounds makes them less suitable as anti-cancer dnjgs. There remains a need for an active compound that is suitable for treating tumors, including cancerous tumors, that is highly efficacious and stable. Summary The present invention provides efficacious deacetylase inhibitor compounds that are useful as pharmaceutical agents having the formula I wherein Ri is H, halo, or a straight chain C1-C6 alkyl (especially methyl, ethyl or n-propyl, which methyl, ethyl and n-propyl substituents are unsubstituted or substituted by one or more substituents described below for alkyl substituents); or a pharmaceutically acceptable salt thereof. The compounds of the present invention are suitable as active agents in pharmaceutical compositions that are efficacious particularly for treating cellular proliferative ailments. The pharmaceutical composition has a pharmaceutically effective amount of the present active agent along with other pharmaceutically acceptable exipients, carriers, fillers, diluents and the like. The term pharmaceutically effective amount as used herein indicates an amount necessary to administer to a host to achieve a therapeutic result, especially an anti-tumor effect, e.g., inhibition of proliferation of malignant cancer cells, benign tumor cells or other proliferative cells. Detailed Description The present invention provides hydroxamate compounds, e.g., hydroxamic acids, that are inhibitors of deacetylases, preferably inhibitors of histone deacetylases. The hydroxamate compounds are highly suitable for treating tumors, including cancerous tumors. The hydroxamate compounds of the present invention have the following structure I heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring; As appropriate, unsubstituted means that there is no substituent or that the only substituents are hydrogen. Halo substituents are selected from fluoro, chloro, bromo and iodo, preferably fluoro or chloro. Alkyl substituents include straight and branched C1-C6alkyI, unless othenvise noted. Examples of suitable straight and branched C1-C6alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, and the like. Unless otherwise noted, the alkyl substituents include both unsubstituted alkyl groups and alkyl groups that are substituted by one or more suitable substituents, including unsaturation (i.e. there are one or more double or triple C-C bonds), acyl, cycloalkyl, halo, oxyalkyi, alkylamino, aminoalkyi, acylamino and OR15, for example, alkoxy. Preferred substituents for alkyl groups include halo, hydroxy, alkoxy, oxyalkyi, alkylamino, and aminoalkyi. Cycloalkyi substituents include C3-C9 cycloalkyi groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified. Unless othenvise noted, cycloalkyi substituents include both unsubstituted cycloalkyi groups and cycloalkyi groups that are substituted by one or more suitable substituents, including C1-C6 alkyl, halo, hydroxy, aminoalkyi, oxyalkyi, alkylamino, and OR15, such as alkoxy. Prefen-ed substituents for cycloalkyi groups include halo, hydroxy, alkoxy, oxyalkyi, alkylamino and aminoalkyi. The above discussion of alkyl and cycloalkyi substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyi, heteroarylalkyi, alkylsulfonyl and alkyl ester substituents and the like. HeterocycloalkyI substituents include 3 to 9 membered aliphatic rings, such as 4 to 7 membered aliphatic rings, containing from one to three heteroatoms selected from nitrogen, sulfur and oxygen. Examples of suitable heterocycloalkyi substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane. Unless othen/vise noted, the rings are unsubstituted or substuted on the carbon atoms by one or more suitable substituents, including C1-Ce alkyl, C4 - C9 cycloalkyi, aryl, heteroaryl, arylalkyi (e.g., benzyl), and heteroarylalkyi (e.g., pyridylmethyl), halo, amino, alkyl amino and OR15, for example alkoxy. Unless othenvise noted, nitrogen heteroatoms are unsubstituted or substituted by H, C1-C4 alkyl, arylalkyi (e.g., benzyl), and heteroarylalkyi (e.g., pyridylmethyl), acyl, aminoacyl, alkylsulfonyl, and arylsulfonyl. CycloalkylalkyI substituents include compounds of the formula -(CH2)n5-cycloalkyl wherein n5 is a number from 1-6. Suitable cycloalkylalkyi substituents include cyclopentylmethyl-, cyclopentylethyl, cyclohexylmethyl and the like. Such substituents are unsubstituted or substituted in the alkyl portion or in the cycloalkyi portion by a suitable substituent, including those listed above for alkyl and cycloalkyi. Aryl substituents include unsubstituted phenyl and phenyl substituted by one or more suitable substituents, including C1-C6 alkyl, cycloalkylalkyi (e.g., cyclopropylmethyl), O(CO)alkyl, oxyalkyi, halo, nitro, amino, alkylamino, aminoalkyi, alkyl ketones, nitrile, carboxyalkyi, alkylsulfonyl, aminosulfonyl, arylsulfonyl, and OR15, such as alkoxy. Preferred substituents include including C1-C6 alkyl, cycloalkyi (e.g., cyclopropylmethyl), alkoxy, oxyalkyi, halo, nitro, amino, alkylamino, aminoalkyi, alkyl ketones, nitrile, carboxyalkyI, alkylsulfonyl, arylsulfonyl, and aminosulfonyl. Examples of suitable aryl groups include Cr C4alkylphenyl, C1-C4alkoxyphenyl, trifluoromethylphenyl, methoxyphenyl, hydroxyethylphenyl, dimethylaminophenyl, aminopropylphenyl, carbethoxyphenyl, methanesulfonylphenyl and tolylsulfonylphenyl. Aromatic polycycles include naphthyl, and naphthyl substituted by one or more suitable substituents, including C1-C6 alkyl, cycloalkylalkyi (e.g., cyclopropylmethyl), oxyalkyi, halo, nitro, amino, alkyiamino, aminoalkyi, alkyl ketones, nitrile, carboxyalkyi, alkylsulfonyl, arylsulfonyl, aminosulfonyl and OR15, such as aikoxy. Heteroaryl substituents include compounds with a 5 to 7 member aromatic ring containing one or more heteroatoms, for example from 1 to 4 heteroatoms, selected from N, O and S. Typical heteroaryl substituents include furyl, thienyl, pyrrole, pyrazole, triazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine and the like. Unless otherwise noted, heteroaryl substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including alkyl, the alkyl substituents identified above, and another heteroaryl substituent. Nitrogen atoms are unsubstituted or substituted, for example by R13; especially useful N substituents include H, C1 - C4 alkyl, acyl, aminoacyl, and sulfonyl. Arylalkyl substituents include groups of the formula -(CH2)n5"aryl, -(CH2)n5-i-(CHaryl)-(CH2)n5"aryl or-(CH2)n5.iCH(aryl)(aryl) wherein aryl and n5 are as defined above. Such arylalkyl substituents include benzyl, 2-phenylethyl, 1-phenylethyl, tolyl-3-propyl, 2-phenylpropyl, diphenylmethyl, 2-diphenylethyl, 5,5-dimethyl-3-phenylpentyl and the like. Arylalkyl substituents are unsubstituted or substituted in the alkyl moiety or the aryl moiety or both as described above for alkyl and aryl substituents. Heteroarylalkyl substituents include groups of the fomiula -(CH2)n5-heteroaryl wherein heteroaryl and n5 are as defined above and the bridging group is linked to a cariDon or a nitrogen of the heteroaryl portion, such as 2-, 3- or 4-pyridylmethyl, imidazolylmethyl, quinolylethyl, and pyrrolylbutyl. Heteroaryl substituents are unsubstituted or substituted as discussed above for heteroaryl and alkyl substituents. Amino acyl substituents include groups of the formula -C(0)-(CH2)n-C(H)(NRi3Ri4)-(CH2)n"R5 wherein n, R13, R14 and R5 are described above. Suitable aminoacyl substituents include natural and non-natural amino acids such as glycinyl, D-tryptophanyl, L-lyslnyl, D- or L-homoserinyl, 4-aminobutryic acyl, ±-3-amin-4-hexenoyl. Non-aromatic polycycle substituents include bicyclic and tricyclic fused ring systems where each ring can be 4-9 membered and each ring can contain zero, 1 or more double and/or triple bonds. Suitable examples of non-aromatic polycycles include decalin, octahydroindene, perhydrobenzocycloheptene, perhydrobenzo-[f]-azulene. Such substituents are unsubstituted or substituted as described above for cycloalkyi groups. Mixed aryl and non-aryl polycycle substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered and at least one ring is aromatic. Suitable examples of mixed aryl and non-aryl polycycles include methylenedloxyphenyl, bi$-methylenedioxyphenyl, 1,2,3,4-tetrahydronaphthalene, dibenzosuberane, dihdydroanthracene, 9H-fluorene. Such substituents are unsubstituted or substituted by njtro or as described above for cycloalkyi groups. Polyheteroaryl substituents include bicyclic and tricyclic fused ring systems where each ring can independently be 5 or 6 membered and contain one or more heteroatom, for example, 1, 2,3, or 4 heteroatoms, chosen from O, N or S such that the fused ring system is aromatic. Suitable examples of polyheteroaryl ring systems include quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole, benzofuran, benzothiofuran, benzindole, benzoxazole, pyrroloquinoline, and the like. Unless othen/vise noted, polyheteroaryl substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including alkyl, the alkyl substituents identified above and a substituent of the formula -O-(CH2CH=CH(CH3)(CH2))i.3H. Nitrogen atoms are unsubstituted or substituted, for example by R13; especially useful N substituents include H, C1 - C4 alkyl, acyl, aminoacyl, and sulfonyl. Non-aromatic polyheterocyclic substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered, contain one or more heteroatom, for example, 1, 2,3, or 4 heteroatoms, chosen from O, N or S and contain zero or one or more C-C double or triple bonds. Suitable examples of non-aromatic polyheterocycles include hexitol, cis-perhydro-cyclohepta[b]pyridinyl, decahydro-benzo[f][1,4]oxazepinyl, 2,8-dioxabicyclo[3.3.0]octane, hexahydro-thieno[3,2-b]thiophene, perhydropyrrolo[3,2-b]pyrrole, periiydronaphthyridine, perhydro-1H-dicyclopenta[b,e]pyran. Unless otherwise noted, non-aromatic polyheterocyclic substituents are unsubstituted or substituted on a carbon atom by one or more substituents, including alkyl and the alkyl substituents identified above. Nitrogen atoms are unsubstituted or substituted, for example, by R13; especially useful N substituents include H, C1 - C4 alkyl. acyl, aminoacyl, and sulfonyl. Mixed aryl and non-aryl polyheterocycles substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered, contain one or more heteroatom chosen from O, N or S, and at least one of the rings must be aromatic* Suitable examples of mixed aryl and non-aryl polyheterocycles include 2,3-dihydroindole, 1,2,3,4-tetrahydroquinoline, 5,11 -dihydro-10H-diben2[b,e][1,4]diazepine, 5H-dibenzo[b,e][1,4]diazepine, 1,2-dihydropyrrolo[3,4-b][1,5]benzodiazepine, 1,5-dihydro-pyrido[2,3-b][1,4]diazepin-4-one, 1,2,3,4,6,11"hexahydro-benzo[b]pyrido[2.3-e][1,4]diazepin-5-one. Unless otherwise noted, mixed aryl and non-aryl polyheterocyclic substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including, -N-OH, =N-OH, alkyl and the alkyl substituents identified above. Nitrogen atoms are unsubstituted or substituted, for example, by R13; especially useful N substituents include H, C1 - C4 alkyl, acyl, aminoacyl, and sulfonyl. Amino substituents include primary, secondary and tertiary amines and in salt fonn, quaternary amines. Examples of amino substituents include mono- and di-alkylamino, mono- and di-aryl amino, mono- and di-arylalkyi amino, aryl-arylalkylamino, alkyl-arylamino. alkyl-arylalkylamino and the like. Sulfonyl substituents include alkylsulfonyl and arylsulfonyl, for example methane sulfonyl, benzene sulfonyl, tosyl and the like. Acyl substituents include groups of the fomriula -C(0)-W, -OC(0)-W, -C(0)-0-W and -C(O)NR13R14. where W is R18, H or cycloalkylalkyl. Acylamino substituents include groups of the formula -N(R12)C(O)-W, "N(R12)C(O)-0-W, and -N(Ri2)C{0)-NH0H and R12 and W are as defined above. The R2 substituent HON-C(O)-CH=C(Ri)-aryl-alkyl- is a group of the formula wherein n4 is 0-3 and X and Y are as defined above. R10 and R11 are the same or different and independently selected from H, C1-C4 alkyl, and -C(O)-alkyl; Useful compounds of the formula I include those wherein each of Ri, X, Y, R3, and R4 is H, including those wherein one of n2 and n3 is zero and the other is 1, especially those wherein R2 is H or-CH2-CH2-OH. One suitable genus of hydroxamate compounds are those of formula la or a pharmaceutically acceptable salt thereof. Another interesting genus are the compounds of fonnula lb Another interesting genus of hydroxamate compounds are the compounds of formula Ic wherein the ring containing Z1 is aromatic or non-aromatic, which non-aromatic rings are saturated or unsaturated, Especially useful compounds of formula Ic are those wherein R2 is H, or -(CH2)pCH2oH, wherein p is 1-3, especially those wherein R1 is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3, especially those wherein Zi is N-R20. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1. Another interesting genus of hydroxamate compounds are the compounds of formula Id Especially useful compounds of formula Id are those wherein R2 is H, or -(CH2)pCH20H, wherein p is 1-3, especially those wherein Ri is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1. The present invention further relates to compounds of the formula le or a phamriaceutically acceptable salt thereof. The variable substituents are as defined above. Especially useful compounds of formula le are those wherein R18 is H, fluoro, chloro, bromo, a C1-C4alkyl group, a substituted C1-C4alkyl group, a Ca-Crcycloalkyl group, unsubstituted phenyl, phenyl substituted in the para position, or a heteroaryl (e.g., pyridyl) ring. Another group of useful compounds of formula le are those wherein R2 is H, or -(CH2)pCH2OH, wherein p is 1-3, especially those wherein R1 is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1. Another group of useful compounds of formula le are those wherein R16 is H, methyl, ethyl, t-butyl, trifluoromethyl, cyclohexyl, phenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 2-furanyl, 2-thiophenyl, or 2-, 3- or 4-pyridyl wherein the 2-furanyl, 2-thiophenyl and 2-, 3- or 4-pyridyl substituents are unsubstituted or substituted as described above for heteroaryl rings; R2 is H, or -(CH2)pCH2OH, wherein p is 1-3; especially those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or-CH2-CH2-OH and the sum of q and r is preferably 1. Those compounds of formula le wherein R20 is H or C1-Ce6lkyl, especially H, are important members of each of the subgenuses of compounds of formula le described above. N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2£-2-propenamide, or a pharmaceutically acceptable salt thereof, are important compounds of fomiula le. The present invention further relates to the compounds of the formula If or a phamiaceutically acceptable salt thereof. The variable substituents are as defined above. Useful compounds of formula If are those wherein R2 is H, or -(CH2)pCH2OH, wherein p is 1-3, especially those wherein R1 is H; such as those wherein R1 is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1. N-hydroxy-3-[4-[[[2-(benzofur-3-yl)"ethyl]-amino]methyl]phenyl]-2E-2-propenamide,or a pharmaceutically acceptable salt thereof, is an important compound of formula If. The compounds described above are often used in the form of a pharmaceutically acceptable salt. Phamiaceutically acceptable salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts. Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate. Examples of metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of ammonium salts are ammonium salt and tetramethylammonium salt. Examples of organic amine addition salts are salts with morpholine and piperidine. Examples of amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine. Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts. As is evident to those skilled in the art, the many of the deacetylase inhibitor compounds of the present invention contain asymmetric carbon atoms. It should be understood, therefore, that the individual stereoisomers are contemplated as being included within the scope of this invention. The hydroxamate compounds of the present invention can be produced by known organic synthesis methods. For example, the hydroxamate compounds can be produced by reacting methyl 4-formyl cinnamate with tryptamine and then converting the reactant to the hydroxamate compounds. As an example, methyl 4-formyl cinnamate 2, is prepared by acid catalyzed esterification of 4-formylcinnamic acid 3 (Bull. Chem. Soc. Jpn. 1995; 68:2355-2362). An altemate preparation of methyl 4-formyl cinnamate 2 is by a Pd-catalyzed coupling of methyl acrylate 4 with 4-bromobenzaldehyde 5. Additional starting materials can be prepared from 4-carboxybenzaldehyde 6, and an exemplary method is illustrated for the preparation of aldehyde 9. shown below. The carboxylic acid in 4-carboxybenzaldehyde 6 can be protected as a silyl ester (e.g., the f-butyldimethylsilyl ester) by treatment with a silyl chloride (e.g., f-butyldimethylsilyl chloride) and a base (e.g. triethylamine) in an appropriate solvent (e.g., dichloromethane). The resulting silyl ester 7 can undergo an olefination reaction (e.g., a Horner-Emmons olefination) with a phosphonate ester (e.g., triethyl 2-phosphonopropionate) in the presence of a base (e.g., sodium hydride) In an appropriate solvent (e.g., tetrahydrofuran (THF)). Treatment of the resulting diester with acid (e.g., aqueous hydrochloric acid) results in the hydrolysis of the silyl ester providing acid 8. Selective reduction of the carboxylic acid of 8 using, for example, borane-dimethylsuflide complex in a solvent (e.g., THF) provides an intermediate alcohol. This intermediate alcohol could be oxidized to aldehyde 9 by a number of known methods, including, but not limited to, Swern oxidation, Dess-Martin periodinane oxidation, Moffatt oxidation and the like. The aldehyde starting materials 2 or 9 can be reductively aminated to provide secondary or tertiary amines. This is illustrated by the reaction of methyl 4-formyl cinnamate 2 with tryptamine 10 using sodium triacetoxyborohydride (NaBH(0Ac)3) as the reducing agent in dichloroethane (DCE) as solvent to provide amine 11. Other reducing agents can be used, e.g.. sodium borohydride (NaBH4) and sodium cyanoborohydride (NaBH3CN), in other solvents or solvent mixtures in the presence or absence of acid catalysts (e.g., acetic acid and trifluoroacetic acid). Amine 11 can be converted directly to hydroxamic acid 12 by treatment with 50% aqueous hydroxylamine in a suitable solvent (e.g., THF in the presence of a base, e.g., NaOH). Other methods of hydroxamate fomiation are known and include reaction of an ester with hydroxylamine hydrochloride and a base (e.g., sodium hydroxide or sodium methoxide) in a suitable solvent or solvent mixture (e.g., methanol, ethanol or methanol/THF). Aldehyde 2 can be reductively aminated with a variety of amines, exemplified by, but not limited to. those illustrated in Table 1. The resulting esters can be converted to target hydroxamates by the methods listed. Table 1 An alternate synthesis of the compounds of this invention starts by reductive amination of 4-formyl cinnamic acid 3, illustrated below with 3-phenylpropylamine 13, using, for example, NaBHgCN as the reducing agent in MeOH and HOAc as a catalyst. The basic nitrogen of the resulting amino acid 14 can be protected, for example, as f-butoxycarbamate (BOC) by reaction with di--t- butyldicarbonate to give 15. The carboxylic acid can be coupled with a protected hydroxylamine (e.g., Otrityl hydroxylamine) using a dehydrating agent (e.g., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI)) and a catalyst (e.g., 1-hydroxybenzotriazole hydrate (HOBT)) in a suitable solvent (e.g., DMF) to produce 16. Treatment of 16 with a strong acid (e.g., trifluoroacetic acid (TFA)) provides a hydroxamic acid 17 of the present invention. Additional examples of compounds that can be prepared by this method are: Tertiary amine compounds can be prepared by a number of methods. Reductive amination of 30 with nicotinaldehyde 32 using NaBHaCN as the reducing agent in dichloroethane and HOAc as a catalyst provides ester 34. Other reducing agents can be used (e.g., NaBH4 and NaBH(0Ac)3) in other solvents or solvent mixtures in the presence or absence of acid catalysts (e.g., acetic acid, trifluoroacetic acid and the like). Reaction of ester 34 with HONH2.HCI. NaOH in MeOH provides hydroxamate 36. Tertiary amine compounds prepared by this methodology are exemplified, but not limited to, those listed in Table 2. An alternate method for preparing tertiary amines Is by reacting a secondary amine with an alkylating agent in a suitable solvent in the presence of a base. For example, heating a dimethylsulfoxide (DMSO) solution of amine 11 and bromide 40 in the presence of (j-Pr)2NEt yielded tertiary amine 42. Reaction of the tertiary amine 42 with HONH2.HCI, NaOH in MeOH provides hydroxamate 43. The silyl group can be removed by any method known to those skilled in the art. For example, the hydroxamate 43 can be treated with an acid, e.g., trifluoroacetic acid, or fluoride to produce hydroxyethyl compound 44. The hydroxamate compound, or salt thereof, is suitable for preparing pharmaceutical compositions, especially pharmaceutical compositions having deacetylase, especially histone deacetylase, inhibiting properties. Studies with athymic mice demonstrate that the hydroxamate compound causes HDA inhibition and increased histone acetylation in vivo, which triggers changes in gene expression that correlate with tumor growth inhibition. The present invention further includes pharmaceutical compositions comprising a pharmaceulically effective amount of one or more of the above-described compounds as active ingredient. Pharmaceutical compositions according to the invention are suitable for enteral, such as oral or rectal, and parenteral administration to mammals, Including man, for the treatment of tumors, alone or in combination with one or more pharmaceutically acceptable carriers. The hydroxamate compound is useful in the manufacture of pharmaceutical compositions having an effective amount the compound in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with (a) diluents; (b) lubricants, (c) binders (tablets); if desired, (d) disintegrants; and/or (e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, the compositions may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain preferably about 1 to 50% of the active ingredient. Suitable formulations also include formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may Include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. As discussed above, the compounds of the present invention are useful for treating proliferative diseases. A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance. In a broader sense of the invention, a proliferative disease may furthemriore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty. Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis. The compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particulariy in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis. In addition, the hydroxamate compound induces p21, cyclin-CDK interacting protein, which induces either apoptosis or G1 arrest in a variety of cell lines. The following examples are intended to illustrate the invention and are not to be construed as being limitations thereto. Example P1 Preparation of A/-Hydroxy-3-[4-[[[2-(1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide. 4-fonTiylcinnamic acid methylester is produced by adding 4-formylcinnamic acid (25 g, 0.143 mol) in MeOH and HCI (6.7 g, 0.18 mol). The resulting suspension is heated to reflux for 3 hours, cooled and evaporated to dryness. The resulting yellow solid is dissolved in EtOAc, the solution washed with saturated NaHCO3, dried (MgSO4) and evaporated to give a pale yellow solid which is used without further purification (25.0 g, 92%). To a solution of tryptamine (16.3 g, 100 mmol) and 4-formylcinnamic acid methylester (19 g, 100 mmol) in dichloroethane, NaBH(0Ac)3 (21 g, 100 mmol) is added. After 4 hours the mixture is diluted with 10% K2CO3 solution, the organic phase separated and the aqueous solution extracted with CH2CI2. The combined organic extracts are dried (Na2SO4), evaporated and the residue purified by flash chromatography to produce 3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester (29 g). A solution of KOH (12.9 g 87%, 0.2 mol) In MeOH (100 mL) is added to a solution of HONH2HCI (13.9 g, 0.2 mol) in MeOH (200 mL) and a precipitate results. After 15 minutes the mixture is filtered, the filter cake washed with MeOH and the filtrate evaporated under vacuum to approximately 75 mL. The mixture is filtered and the volume adjusted to 100 mL with MeOH. The resulting solution 2M HONH2 is stored under N2 at -20o C for up to 2 weeks. Then 3-(4-{[2-(1 Wndol-3-yl)-ethylamino]-methyl}-phenyl)-(2e)-2-propenoic acid methyl ester (2.20 g, 6.50 mmol) is added to 2 M HONH2 in MeOH (30 mL, 60 mmol) followed by a solution of KOH (420 mg, 6.5 mmol) in MeOH (5 mL). After 2 hours dry ice is added to the reaction and the mixture is evaporated to dryness. The residue is dissolved in hot MeOH (20 mL), cooled and stored at -20oC ovemight. The resulting suspension is filtered, the solids washed with ice cold MeOH and dried under vacuum, producing A/-Hydroxy-3-[4-[[[2-(1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (m/z 336 [MH_+]). Example P2 Preparation of N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indoN3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide A solution of 3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2£)-2-propenoic acid methyl ester (12.6 g, 37.7 mmol). (2-bromoethoxy)-tert-butyldimethylsilane (12.8 g, 53.6 mmol), (i-Pr)2NEt. (7.42 g, 57.4 mmol) in DMSO (100 mL) is heated to 50° 0. After 8 hours the mixture is partitioned with CH2CI2/H2O. The organic layer is dried (Na2SO4) and evaporated. The residue is chromatographed on silica gel to produce 3-[4-({[2-(tert-butyldimethylsilanyloxy)-ethyl]-[2-(1Wndol-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2E)-2-propenoic acid methyl ester (13.1 g). Following the procedure described for the preparation of the hydroxamate compound in Example PI, 3-[4-(([2-(tert-butyldimethylsilanyloxy)-ethyl]-[2-(1 W-indoI-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2E)-2-propenoic acid methyl ester (5.4 g. 11 mmol) is converted to N-hydroxy-3-[4-({[2-(tert-butyldimethylsilanyloxy)-ethyl]-[2-(1 H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2£)-2-propenamide (5.1 g,) and used without further purification. The hydroxamic acid (5.0 g, 13.3 mmol) is then dissolved in 95% TFA/H2O (59 mL) and heated to 40 - 50 °C for 4 hours. The mixture is evaporated and the residue purified by reverse phase HPLC to produce N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1/+indol-3-yl)-ethyll-amino]methyl]phenyl]-2E-2-propenamide as the trifluoroacetate salt (m/z 380 [MHI). Example P3 Preparation of N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyI]phenyl]-2E'-2-propenamicle. A suspension of LiIH4 (17 g, 445 mmol) in dry THF (1000 mL) is cooled to 0 ^C and 2-methylindole-3-glyoxylamide (30 g, 148 mmol) is added in portions over 30 min. The mixture is stirred at room temperature for 30 min. and then maintained at reflux for 3 h. The reaction is cooled to 0 °C and treated with H2O (17ml), 15% NaOH (aq., 17ml) and H2O (51ml), The mixture is treated with MgSO4, filtered and the filtrate evaporated to give 2-methyltryptamine which is dissolved in MeOH. Methyl 4-fonnylcinnamate (16.9 g, 88.8 mmol) is added to the solution, followed by NaBHsCN (8.4 g) and AcOH (1 equiv,). After 1h the reaction Is diluted with NaHCO2(aq.) and extracted with EtOAc. The organic extracts are dried (MgSO4), filtered and evaporated. The residue is purified by chromatography to give 3-(4-{[2-(2-methyl-1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester. The ester is dissolved In MeOH, 1.0 M HCI/dioxane (1-1.5 equiv.) is added followed by Et2O. The resulting precipitate is filtered and the solid washed with Et2O and dried thoroughly to gfve 3-(4-{[2-(2-methyl-1 H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester hydrochloride. 1,0 M NaOH (aq., 85 mL) is added to an ice cold solution of the methyl ester hydrochloride (14.9 g, 38.6 mmol) and HONH2 (50% aq. solution, 24.0 mL, ca. 391.2 mmol). After 6 h, the ice cold solution is diluted with H2O and NH4CI (aq., 0.86 M, 100 ml). The resulting precipitate is filtered, washed with H2O and dried to afford N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (m/z 350 [MH1). Examples 1-265 The following compounds are prepared by methods analogous to those disclosed in Examples PI, P2 and P3: The compounds of Examples 1-265 show an HDA enzyme IC50 in the range from about 0.005 to about 0.5 jiM. Example B1 Cell lines H1299 (human lung carcinoma cell) and HCT116 (colon tumor cell) are obtained from the American Type Culture Collection, Rockville, MD. The cell lines are free of Mycoplasma contamination (Rapid Detection System by Gen-Probe, Inc., San Diego, CA) and viral contamination (MAP testing by MA BioServices, Inc., Rockville, MD). The cell lines are propagated and expanded in RPM11640 medium containing 10% heat-inactivated FBS (Life Technologies, Grand Island, NY). Cell expansions for implantation are perfomied in cell factories (NUNC, purchased from Fisher Scientific, Springfield, NJ). Cells are harvested at 50-90% confluency, washed once with HBSS (Hank's Balanced Salt Solution) containing 10% FBS, and suspended in 100% HBSS. Cell proliferation is measured with a commercial MTS kit (Promega, Madision, Wis.) assay using an adaptation of published procedures, for example, that disclosed in Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Alley MC, et a!., Cancer Res. 1988; 48:589-601. Cells are plated in 96-well tissue culture dishes, with top and bottom rows left empty. H1299 and HCT116 cells are suspended in complete media at a density of 5.3 x 103 and 3.6 x 10^ cell/mL, respectively, and 190 μl are added per well. Each cell line is added to one half of the plate. Complete medium (200 μL) is added to the top and bottom rows. Twenty-four hours later, 10 μl of MTS solution is added to one of the plates to determine the activity at the time of compound addition (To). The plate is incubated at 37oC for 4 hours and the OD490 is measured on a Molecular Devices Thermomax at 490 nm using the Softmax program. The To plate serves as a reference for initial activity at the beginning of the experiment. Five serial dilutions (1:4) of each compound are made in a 96-deep well plate with the highest concentrations on the edge of plate. Two cell lines are tested with two compounds per plate. Ten microliters of each of the five dilutions are added in triplicate and complete medium alone is added to columns six and seven. The plates are incubated at 37 °C for 72 hours. The MTS solution is added (as for the To plate) and read four hours later. In order to analyze the data, the average background value (media alone) is subtracted from each experimental well; the triplicate values are averaged for each compound dilution. The following formulas are used to calculate percent growth. If X > To. % Growth = ((X-To)/(GC -To)) x 100 If X in which To = (average value of cell viability at time 0) - background GC = average value of untreated cells (in triplicate) - background X = average value of compound treated cells (in triplicate) - background The *% Growth- is plotted against compound concentration and used to calculate IC50S employing the linear regression techniques between data points to predict the concentration of compounds at 50% inhibition. Lactate salts of N-hydroxy-3-[4-[[[2-(1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD1), N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD2), N-hydroxy-3-[4-[[[2-(5-methoxy-1 H indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide(CMD3), N-hydroxy-3-[4-[[[2-(5-fluoro-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD4), N-hydroxy-3-[4-[[[2-(benzofur-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD5) having a purity of higher than 95% are dissolved in pure dimethylsulfoxide (DMSO) to create a stock solution. The stock solution is diluted with 5% dextrose injection, USP, Just prior to dosing. In addition, N-(2-aminophenyl)-4-[N-pyridin-3-yl)methoxycarbonylaminomethyl]benzamide is synthesized in accordance with Example 48 of EP 0 847 992 and used as a control compound (CMDC). Inhibition of cell growth in monolayer for 72 hours of compound treatment is measured in triplicate experiments and used to derive the IC50 by MTS assay. The results are shown in Table B1. Table B1 Compound CMD1 CMD2 CMD3 CMD4 CMD5 CMDC Monolaver Growth IC50 (μ.M) H1299 HCT116 0.40 0.03 0.15 0.01 0.58 0.03 0.28 0.03 0.18 0.03 6.8 0.67 The results show that the hydroxamate compounds of the present invention are highly active in inhibition of tumor cell growth. In addition to the above results, it has been observed that the compounds selectively inhibited tumor cells while showing minimal inhibition activities in non-tumorous cells. The cells treated with the hydroxamate compounds are also tested for the induction of p21 promoter, which is a key mediator of G1 arrest and differentiation. The hydroxamate compounds activate the p21 promoter to a readily detectable level at a concentration within two-fold of their respective IC50 for monolayer cell growth inhibition in H1299. Without being bound by any particular theory, the correlation appears to demonstrate that HDA inhibition leads to transcriptional activation of genes that inhibit tumor cell proliferation. Example B2 HDA is partially purified from H1299, human non-small cell lung carcinoma cells (obtained from American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, USA). Cells are grown to 70-80% confluence in RPMI media in the presence of 10% FCS, harvested and lysed by sonication. The lysate is centrifuged at 23, 420g for 10-15 min, the supernatant is applied to a Hiload 26/10 High performance Q-sepharose column (Amersham Phamiacia Biotech), and equilibrated with a buffer containing 20 mM Tris pH8.0,1 mM EDTA, 10 mM NH4CI2,1 mM p-Mercaptoethanol, 5% glycerol. 2 μg/mL aprotinin, 1 μg/mL leupeptin, and 400 mM PMSF. Proteins are eluted in 4mL aliquotes with a linear gradient from 0-500 mM NaCI in the above buffer at a flow rate of 2.5 mL/min. Each preparation of partially purified HDA enzyme is titrated to determine the optimal amount needed to obtain a signal to noise ratio of at least 5 to 1. Generally, 20-30 μl of partially purified HDA (5-10 mg protein/mL) is mixed with 2 μL of compound solution in DMSO in a deep well titer plate (Beckman). The compounds are serially diluted in DMSO to generate stocks at 20-fold of the assay concentrations. Final concentrations of compounds in the assay are 10μM, 2μM, 400 nM, 80 nM, and 16 nM with the final percentage of DMSO in each enzyme reaction equaling 0.1%. Each concentration of compound is assayed in duplicate. The substrate used in the reaction is a peptide of amino acid sequence, SGRGKGGKGLGKGGAKRHRKVLRD, corresponding to the twenty-four N-terminal amino acids of human histone H4, biotinylated at the N-terminus and penta-acetylated, at each lysine residue with 3H-acetate. To Initiate the reaction, the substrate Is diluted in 10 jiL of Buffer A (100 mM Tris pH 8.0, 2 mM EDTA). added to the enzyme mixture and collected at the bottom of the deep well plate by centrifugation for 5 minutes at 1500 rpm. Following centrifugation, the mixture is incubated at 37 °C for 1.5 hr. The reaction is stopped by the addition of 20 μL of the Stop Buffer (0.5N HCI, 0.08M Acetic Acid). At this point, the assay proceeds to the robotic extraction phase or is frozen for several days at -80 °C. The extraction of enzymatically cleaved 3H-acetate groups from the reaction mixture is achieved with the solvent TBME (t-butyl methyl ether) using the Tomtec Quadra 96 workstation. A program is written to add 200 μL of TBME to a 96 -deep well- plate. The workstation is programmed to aspirate 50 μL of air followed by 200 μL of TBME and finally another 25 pL of air, which is dispensed into the each well of the plate. The contents of the deep well were mixed thoroughly by pipetting 160 μL up and down 10 times. Before addition of TBME to the reaction mixture, it is necessary to -pre-wef the pipette tips with TBME to prevent the solvent from dripping during the transfer to the deep well plate. The organic and aqueous phases in the deep well are separated by centrifugation at 1500 rpm for 5 min. Opti-Phase Supermix liquid scintillation cocktail (200 μL) (Wallac) is added to each well of the 96-well Trilux plate (Wallac). The deep well and Trilux plates are placed back on the workstation programmed to aspirate 25 pL of air into the pipette tips followed by 100 pL of the upper TBME phase and transfer It Into the Trilux plate. The solutions are mixed by pipetting and expelling 50 pL, five times, within the same well. The Trilux plate is covered with clear film and read on a 1450 MicroBeta Trilux liquid scintillation and luminescence counter (Wallac) with a color/chemical quench and dpm correction. In order to determine the IC50 values, the data are analyzed on a spreadsheet. The analysis requires a correction for the background luminescence that is accomplished by subtracting the dpm values of wells without 3H substrate from the experimental wells. The corrected dpm values along with the concentrations of the compounds are used to calculate IC50 using the user-defined spline function. This function utilizes linear regression techniques between data points to calculate the concentration of compounds that produced 50% inhibition. The results are shown in Table B2. Table B2 ComDOund HDA Enzvme Activity 1055μM CMD1 0.032 CMD2 0.063 CMD3 0.014 CMD4 0.014 CMD5 0.016 CMDC >10 Example 83 The A549 non-small cell lung human tumor cell line is purchased from the American Type Culture Collection, Rockville, MD. The cell line is free of Mycoplasma contamination (Rapid Detection System by Gen-Probe, Inc., San Diego, CA) and viral contamination (MAP testing by MA BioServices, Inc., Rockville, MD). The cell line is propagated and expanded in RPMI 1640 medium containing 10% heat-inactivated PBS (Life Technologies, Grand Island, NY). Cell expansions for implantation are performed in cell factories (NUNC, purchased from Fisher Scientific, Springfield, NJ). Cells are harvested at 50-90% confluency, washed once with HBSS containing 10% PBS, and suspended in 100% HBSS. Outbred athymic (nu/nu) female mice (-Hsd:Athymic Nude-nu- from Marian Sprague Dawley, Indianapolis, IN) are anesthetized with Metofane (Mallinckrodt Veterinary, Inc., Mundelein, IL), and 100 μL of the cell suspension containing 1x107 cells is injected subcutaneously into the right axillary (lateral) region of each animal. Tumors are allowed to grow for about 20 days until a volume of -100 mm3 is achieved. At this point, mice bearing tumors with acceptable morphology and size are sorted into groups of eight for the study. The sorting process produces groups balanced with respect to mean and range of tumor size. Antitumor activity is expressed as % T/C, comparing differences in tumor volumes for treatment group (T) to vehicle control group (C). Regressions are calculated using the formula: (1-T/To) x 100%. where T is the tumor volume for the treatment group at the end of the experiment, and To is the tumor volume at the beginning of the experiment. CMD1 is administered intravenously, once daily 5x/week for three weeks, at doses of 10, 25, 50, or 100 mg/kg. The final DMSO concentration is 10%. Each test group has eight mice. Tumors are measured, and individual animal body weights recorded. Table B3 shows the results on the 41st day. Note:1. Difference in mean tumor volume for a group of animals at the end of the experiment minus mean tumor volume at the beginning. 2. Difference in body weight for a group of animals at the end of the experiment minus mean tumor volume at the beginning. 3. Standard error of the mean. 4.5% dextrose injection, USP. Example B4 Example B3 repeated except CMD2 is used. Table B4 shows the results. Example B5 Example B3 is repeated except the HCT116 colon tumor cell line is used in place of the A549 cell line. The HCT116 cell line Is also obtained from American Type Culture Collection, Rockviile, MD, and the cell line is free of Mycoplasma contamination and viral contamination. The results are recorded on the 34th day and are shown in Table 85. Table B5 Example B6 Example B4 is repeated except the HCT116 colon tumor cell line is used in place of the A549 cell line. The HCT116 is also obtained from American Type Culture Collection, Rockville, MD. and the cell line is free of Mycoplasma contamination and viral contamination. The results are recorded on the 34^ day and are shown in Table B6. Annexin V binding was used as a marker for the early stages of apoptosis. A549, HCT116 and Normal Demrial Human Fibroblasts (NDHF) cells are treated separately with four compounds (CMD1, CMD2, CMD3 and CMD4) for 24 or 48 hours, stained with annexin V and compared to cells treated similarly with vehicle (DMSO). Cells are examined by fluorescence microscopy. Those undergoing apoptosis exhibit green fluorescent membrane staining. Viability is assessed by the counterstain, propidium iodide. Cells detected by red fluorescence are not viable. A small percentage of A549 and the majority of HCT116 cells exhibit cell surface staining with annexin V after 24 hour exposure to each of the four compounds. After 48 hour treatment, the majority of the A549 and HCT116 stain with annexin V and/or propidium iodide indicating that the compounds induce apoptotic cell death. In contrast, NDHF cells do not show noticeable annexin V staining after 24 hour exposure and limited annexin V staining with CMD3 after 48 hour. These data show that NDHF cells predominantly underwent non-lethal growth arrest upon compound treatment, consistent with the cell cycle profile. The staining results demonstrate that the hydroxamate compounds of the present invention cause tumor cells to die by apoptosis, while causing normal fibroblast to predominantly undergo cell cycle arrest, clearly demonstrating the selective efficacy of the present compounds. What is claimed is: 1. A compound of the formula I 2. A compound of claim 1 wherein each of R1, X, Y, R3, and R4 is H. 3. A compound of ciaim 2 wherein one of n2 and n3 is zero and the other is 1, 4. A compound of claim 3 wherein R2 is H or-CH2-CH2-OH. 5. A compound of claim 1 of the formula la or a pharmaceutically acceptable salt thereof. 6. A compound of claim 1 of the formula la R5' is aryl, arylalkyi, an aromatic polycycle, a non-aromatic polycycle or a mixed aryl and non-aryl polycycle, or a pharmaceutically acceptable salt thereof. 7. A compound of claim 6 wherein R5' is aryl or arylalkyi. 8. A compound of claim 7 wherein R5' is p-fluorophenyl, p-chlorophenyl, p-O-C1-C4-alkylphenyl, p-C1-C4-alkylphenyl, benzyl, ortho, meta or para-fluorobenzyl. ortho, meta or para-chlorobenzyl, or ortho, meta or para - mono, di or tri-O-C1-C4-alkylbenzyl. wherein R2' is selected from H, C1-C6 alkyl, C4-C6 cycloalkyi, cycloalkylalkyi, -(CH2)2-4OR21 where R21 is H, methyl, ethyl, propyl, or isopropyl, and R5" is unsubstituted or substituted 1 H-indol-3-yl, benzofuran-3-yl or quinolin-3-yl, or a pharmaceutically acceptable salt thereof. 10, A compound of claim 9 wherein R5" is substituted 1H indol-3-yl or substituted benzofuran-3-yl. 11. A compound of claim 1 of the formula Ic wherein the ring containing Z1 is aromatic or non-aromatic which non-aromatic rings are saturated or unsaturated, Zi is O, S or N-R20; or a pharmaceutically acceptable salt thereof. 12. A compound of claim 11 wherein Z^ is N-R20. 13. A compound of claim 11 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1. 14. A compound of claim 1 of the formula Id 15. A compound of claim 14 wherein R2 is H or-CH2-CH2-OH and the sum of q and r is 1. 16. A compound of claim 11 of the formula le C-cycloalkyI, phenyl or heteroaryl. 18. A compound of claim 16 wherein R2 is H, or -(CH2)pCH2OH and wherein p is 1-3. 19. A compound of claim 18 wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1 -3. 21. A compound of claim 20 wherein R2 is H, or -(CH2)pCH2OH. 22. A compound of claim 21 wherein p is 1-3. 23. A compound of claim 22 wherein R1 is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. 24. A compound of claim 23 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1. 27. A compound of claim 26 which is N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof. 28. A compound of claim 11 of the formula If or a pharmaceutically acceptable salt thereof. or a pharmaceutically acceptable salt thereof. 34. A pharmaceutical composition of claim 33 wherein the compound of fomnula 1 is selected from the group consisting of N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H"-ndol-3- yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1HHndol-3-yl)ethyl]- amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4"[[[2-(2"methyl-1H-indol-3-yl)- ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a phannaceutically acceptable salt thereof. 35. A phamiaceutical composition of claim 34 wherein the compound of formula I is N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a phamiaceutically acceptable salt thereof. 36. A phamiaceutical composition of claim 33 wherein the compound of formula I is N-hydroxy-3-[4-[[[2-(benzofur-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof. 37. A method for treating a proliferative disorder in a mammal which comprises administering to said mammal a compound of the formula I together with the carbon to which it is bound can form a C4 - C9 heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring; or a pharmaceutically acceptable salt thereof, into the environment of a mammalian cell. 40. A method of claim 39 wherein the compound of formula I is selected from the group consisting of N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof. 41. A compound substantially as herein described and exemplified. 42. A pharmaceutical composition substantially as herein described and exemplified.

Full Text

DEACETYLASE INHIBITORS
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. The inventive compounds are useful as pharmaceuticals for the treatment of proliferative diseases.
Background
Reversible acetylation of histones is a major regulator of gene expression that acts by altering accessibility of transcription factors to DNA. In normal cells, histone deacetylase (HDA) and histone acetyltrasferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDA results in the accumulation of hyperacetylated histones, which results in a variety of cellular responses.
Inhibitors of HDA have been studied for their therapeutic effects on cancer cells. For example, butyric acid and its derivatives, including sodium phenylbutyrate, have been reported to induce apoptosis in vitro in human colon carcinoma, leukemia and retinoblastoma cell lines. However, butyric acid and its derivatives are not useful phamnacological agents because they tend to be metabolized rapidly and have a very short half-life in vivo. Other inhibitors of HDA that have been widely studied for their anti-cancer activities are trichostatin A and trapoxin. Trichostatin A is an antifungal and antibiotic and is a reversible inhibitor of mammalian HDA. Trapoxin is a cyclic tetrapeptide, which is an irreversible inhibitor of mammalian HDA. Although trichostatin and trapoxin have been studied for their anti-cancer activities, the in vivo instability of the compounds makes them less suitable as anti-cancer dnjgs. There remains a need for an active compound that is suitable for treating tumors, including cancerous tumors, that is highly efficacious and stable.
Summary
The present invention provides efficacious deacetylase inhibitor compounds that are useful as pharmaceutical agents having the formula I

wherein
Ri is H, halo, or a straight chain C1-C6 alkyl (especially methyl, ethyl or n-propyl, which methyl, ethyl and n-propyl substituents are unsubstituted or substituted by one or more substituents described below for alkyl substituents);

or a pharmaceutically acceptable salt thereof.
The compounds of the present invention are suitable as active agents in pharmaceutical compositions that are efficacious particularly for treating cellular proliferative ailments. The pharmaceutical composition has a pharmaceutically effective amount of the

present active agent along with other pharmaceutically acceptable exipients, carriers, fillers, diluents and the like. The term pharmaceutically effective amount as used herein indicates an amount necessary to administer to a host to achieve a therapeutic result, especially an anti-tumor effect, e.g., inhibition of proliferation of malignant cancer cells, benign tumor cells or other proliferative cells.
Detailed Description
The present invention provides hydroxamate compounds, e.g., hydroxamic acids, that are inhibitors of deacetylases, preferably inhibitors of histone deacetylases. The hydroxamate compounds are highly suitable for treating tumors, including cancerous tumors. The hydroxamate compounds of the present invention have the following structure I

heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring;

As appropriate, unsubstituted means that there is no substituent or that the only substituents are hydrogen.
Halo substituents are selected from fluoro, chloro, bromo and iodo, preferably fluoro or chloro.
Alkyl substituents include straight and branched C1-C6alkyI, unless othenvise noted. Examples of suitable straight and branched C1-C6alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, and the like. Unless otherwise noted, the alkyl substituents include both unsubstituted alkyl groups and alkyl groups that are substituted by one or more suitable substituents, including unsaturation (i.e. there are one or more double or triple C-C bonds), acyl, cycloalkyl, halo, oxyalkyi, alkylamino, aminoalkyi, acylamino and OR15, for example, alkoxy. Preferred substituents for alkyl groups include halo, hydroxy, alkoxy, oxyalkyi, alkylamino, and aminoalkyi.
Cycloalkyi substituents include C3-C9 cycloalkyi groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified. Unless othenvise noted, cycloalkyi substituents include both unsubstituted cycloalkyi groups and cycloalkyi groups that are substituted by one or more suitable substituents, including C1-C6 alkyl, halo, hydroxy, aminoalkyi, oxyalkyi, alkylamino, and OR15, such as alkoxy. Prefen-ed substituents for cycloalkyi groups include halo, hydroxy, alkoxy, oxyalkyi, alkylamino and aminoalkyi.

The above discussion of alkyl and cycloalkyi substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyi, heteroarylalkyi, alkylsulfonyl and alkyl ester substituents and the like.
HeterocycloalkyI substituents include 3 to 9 membered aliphatic rings, such as 4 to 7 membered aliphatic rings, containing from one to three heteroatoms selected from nitrogen, sulfur and oxygen. Examples of suitable heterocycloalkyi substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane. Unless othen/vise noted, the rings are unsubstituted or substuted on the carbon atoms by one or more suitable substituents, including C1-Ce alkyl, C4 - C9 cycloalkyi, aryl, heteroaryl, arylalkyi (e.g., benzyl), and heteroarylalkyi (e.g., pyridylmethyl), halo, amino, alkyl amino and OR15, for example alkoxy. Unless othenvise noted, nitrogen heteroatoms are unsubstituted or substituted by H, C1-C4 alkyl, arylalkyi (e.g., benzyl), and heteroarylalkyi (e.g., pyridylmethyl), acyl, aminoacyl, alkylsulfonyl, and arylsulfonyl.
CycloalkylalkyI substituents include compounds of the formula -(CH2)n5-cycloalkyl wherein n5 is a number from 1-6. Suitable cycloalkylalkyi substituents include cyclopentylmethyl-, cyclopentylethyl, cyclohexylmethyl and the like. Such substituents are unsubstituted or substituted in the alkyl portion or in the cycloalkyi portion by a suitable substituent, including those listed above for alkyl and cycloalkyi.
Aryl substituents include unsubstituted phenyl and phenyl substituted by one or more suitable substituents, including C1-C6 alkyl, cycloalkylalkyi (e.g., cyclopropylmethyl), O(CO)alkyl, oxyalkyi, halo, nitro, amino, alkylamino, aminoalkyi, alkyl ketones, nitrile, carboxyalkyi, alkylsulfonyl, aminosulfonyl, arylsulfonyl, and OR15, such as alkoxy. Preferred substituents include including C1-C6 alkyl, cycloalkyi (e.g., cyclopropylmethyl), alkoxy, oxyalkyi, halo, nitro, amino, alkylamino, aminoalkyi, alkyl ketones, nitrile, carboxyalkyI, alkylsulfonyl, arylsulfonyl, and aminosulfonyl. Examples of suitable aryl groups include Cr C4alkylphenyl, C1-C4alkoxyphenyl, trifluoromethylphenyl, methoxyphenyl, hydroxyethylphenyl, dimethylaminophenyl, aminopropylphenyl, carbethoxyphenyl, methanesulfonylphenyl and tolylsulfonylphenyl.

Aromatic polycycles include naphthyl, and naphthyl substituted by one or more suitable substituents, including C1-C6 alkyl, cycloalkylalkyi (e.g., cyclopropylmethyl), oxyalkyi, halo, nitro, amino, alkyiamino, aminoalkyi, alkyl ketones, nitrile, carboxyalkyi, alkylsulfonyl, arylsulfonyl, aminosulfonyl and OR15, such as aikoxy.
Heteroaryl substituents include compounds with a 5 to 7 member aromatic ring containing one or more heteroatoms, for example from 1 to 4 heteroatoms, selected from N, O and S. Typical heteroaryl substituents include furyl, thienyl, pyrrole, pyrazole, triazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine and the like. Unless otherwise noted, heteroaryl substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including alkyl, the alkyl substituents identified above, and another heteroaryl substituent. Nitrogen atoms are unsubstituted or substituted, for example by R13; especially useful N substituents include H, C1 - C4 alkyl, acyl, aminoacyl, and sulfonyl.
Arylalkyl substituents include groups of the formula -(CH2)n5"aryl, -(CH2)n5-i-(CHaryl)-(CH2)n5"aryl or-(CH2)n5.iCH(aryl)(aryl) wherein aryl and n5 are as defined above. Such arylalkyl substituents include benzyl, 2-phenylethyl, 1-phenylethyl, tolyl-3-propyl, 2-phenylpropyl, diphenylmethyl, 2-diphenylethyl, 5,5-dimethyl-3-phenylpentyl and the like. Arylalkyl substituents are unsubstituted or substituted in the alkyl moiety or the aryl moiety or both as described above for alkyl and aryl substituents.
Heteroarylalkyl substituents include groups of the fomiula -(CH2)n5-heteroaryl wherein heteroaryl and n5 are as defined above and the bridging group is linked to a cariDon or a nitrogen of the heteroaryl portion, such as 2-, 3- or 4-pyridylmethyl, imidazolylmethyl, quinolylethyl, and pyrrolylbutyl. Heteroaryl substituents are unsubstituted or substituted as discussed above for heteroaryl and alkyl substituents.
Amino acyl substituents include groups of the formula -C(0)-(CH2)n-C(H)(NRi3Ri4)-(CH2)n"R5 wherein n, R13, R14 and R5 are described above. Suitable aminoacyl substituents include natural and non-natural amino acids such as glycinyl, D-tryptophanyl, L-lyslnyl, D- or L-homoserinyl, 4-aminobutryic acyl, ±-3-amin-4-hexenoyl.

Non-aromatic polycycle substituents include bicyclic and tricyclic fused ring systems where each ring can be 4-9 membered and each ring can contain zero, 1 or more double and/or triple bonds. Suitable examples of non-aromatic polycycles include decalin, octahydroindene, perhydrobenzocycloheptene, perhydrobenzo-[f]-azulene. Such substituents are unsubstituted or substituted as described above for cycloalkyi groups.
Mixed aryl and non-aryl polycycle substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered and at least one ring is aromatic. Suitable examples of mixed aryl and non-aryl polycycles include methylenedloxyphenyl, bi$-methylenedioxyphenyl, 1,2,3,4-tetrahydronaphthalene, dibenzosuberane, dihdydroanthracene, 9H-fluorene. Such substituents are unsubstituted or substituted by njtro or as described above for cycloalkyi groups.
Polyheteroaryl substituents include bicyclic and tricyclic fused ring systems where each ring can independently be 5 or 6 membered and contain one or more heteroatom, for example, 1, 2,3, or 4 heteroatoms, chosen from O, N or S such that the fused ring system is aromatic. Suitable examples of polyheteroaryl ring systems include quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole, benzofuran, benzothiofuran, benzindole, benzoxazole, pyrroloquinoline, and the like. Unless othen/vise noted, polyheteroaryl substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including alkyl, the alkyl substituents identified above and a substituent of the formula -O-(CH2CH=CH(CH3)(CH2))i.3H. Nitrogen atoms are unsubstituted or substituted, for example by R13; especially useful N substituents include H, C1 - C4 alkyl, acyl, aminoacyl, and sulfonyl.
Non-aromatic polyheterocyclic substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered, contain one or more heteroatom, for example, 1, 2,3, or 4 heteroatoms, chosen from O, N or S and contain zero or one or more C-C double or triple bonds. Suitable examples of non-aromatic polyheterocycles include hexitol, cis-perhydro-cyclohepta[b]pyridinyl, decahydro-benzo[f][1,4]oxazepinyl, 2,8-dioxabicyclo[3.3.0]octane, hexahydro-thieno[3,2-b]thiophene, perhydropyrrolo[3,2-b]pyrrole, periiydronaphthyridine, perhydro-1H-dicyclopenta[b,e]pyran. Unless otherwise noted, non-aromatic polyheterocyclic substituents are unsubstituted or substituted on a carbon atom by one or more substituents, including alkyl and the alkyl substituents identified above.

Nitrogen atoms are unsubstituted or substituted, for example, by R13; especially useful N substituents include H, C1 - C4 alkyl. acyl, aminoacyl, and sulfonyl.
Mixed aryl and non-aryl polyheterocycles substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered, contain one or more heteroatom chosen from O, N or S, and at least one of the rings must be aromatic* Suitable examples of mixed aryl and non-aryl polyheterocycles include 2,3-dihydroindole, 1,2,3,4-tetrahydroquinoline, 5,11 -dihydro-10H-diben2[b,e][1,4]diazepine, 5H-dibenzo[b,e][1,4]diazepine, 1,2-dihydropyrrolo[3,4-b][1,5]benzodiazepine, 1,5-dihydro-pyrido[2,3-b][1,4]diazepin-4-one, 1,2,3,4,6,11"hexahydro-benzo[b]pyrido[2.3-e][1,4]diazepin-5-one. Unless otherwise noted, mixed aryl and non-aryl polyheterocyclic substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including, -N-OH, =N-OH, alkyl and the alkyl substituents identified above. Nitrogen atoms are unsubstituted or substituted, for example, by R13; especially useful N substituents include H, C1 - C4 alkyl, acyl, aminoacyl, and sulfonyl.
Amino substituents include primary, secondary and tertiary amines and in salt fonn, quaternary amines. Examples of amino substituents include mono- and di-alkylamino, mono- and di-aryl amino, mono- and di-arylalkyi amino, aryl-arylalkylamino, alkyl-arylamino. alkyl-arylalkylamino and the like.
Sulfonyl substituents include alkylsulfonyl and arylsulfonyl, for example methane sulfonyl, benzene sulfonyl, tosyl and the like.
Acyl substituents include groups of the fomriula -C(0)-W, -OC(0)-W, -C(0)-0-W and -C(O)NR13R14. where W is R18, H or cycloalkylalkyl.
Acylamino substituents include groups of the formula -N(R12)C(O)-W, "N(R12)C(O)-0-W, and -N(Ri2)C{0)-NH0H and R12 and W are as defined above.
The R2 substituent HON-C(O)-CH=C(Ri)-aryl-alkyl- is a group of the formula

wherein n4 is 0-3 and X and Y are as defined above.

R10 and R11 are the same or different and independently selected from H, C1-C4 alkyl, and -C(O)-alkyl;

Useful compounds of the formula I include those wherein each of Ri, X, Y, R3, and R4 is H, including those wherein one of n2 and n3 is zero and the other is 1, especially those wherein R2 is H or-CH2-CH2-OH.
One suitable genus of hydroxamate compounds are those of formula la

or a pharmaceutically acceptable salt thereof.
Another interesting genus are the compounds of fonnula lb

Another interesting genus of hydroxamate compounds are the compounds of formula Ic

wherein
the ring containing Z1 is aromatic or non-aromatic, which non-aromatic rings are saturated or unsaturated,

Especially useful compounds of formula Ic are those wherein R2 is H, or -(CH2)pCH2oH, wherein p is 1-3, especially those wherein R1 is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3, especially those wherein Zi is N-R20. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
Another interesting genus of hydroxamate compounds are the compounds of formula Id

Especially useful compounds of formula Id are those wherein R2 is H, or -(CH2)pCH20H, wherein p is 1-3, especially those wherein Ri is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
The present invention further relates to compounds of the formula le

or a phamriaceutically acceptable salt thereof. The variable substituents are as defined above.
Especially useful compounds of formula le are those wherein R18 is H, fluoro, chloro, bromo, a C1-C4alkyl group, a substituted C1-C4alkyl group, a Ca-Crcycloalkyl group, unsubstituted phenyl, phenyl substituted in the para position, or a heteroaryl (e.g., pyridyl) ring.

Another group of useful compounds of formula le are those wherein R2 is H, or -(CH2)pCH2OH, wherein p is 1-3, especially those wherein R1 is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
Another group of useful compounds of formula le are those wherein R16 is H, methyl, ethyl, t-butyl, trifluoromethyl, cyclohexyl, phenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 2-furanyl, 2-thiophenyl, or 2-, 3- or 4-pyridyl wherein the 2-furanyl, 2-thiophenyl and 2-, 3- or 4-pyridyl substituents are unsubstituted or substituted as described above for heteroaryl rings; R2 is H, or -(CH2)pCH2OH, wherein p is 1-3; especially those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or-CH2-CH2-OH and the sum of q and r is preferably 1.
Those compounds of formula le wherein R20 is H or C1-Ce6lkyl, especially H, are important members of each of the subgenuses of compounds of formula le described above.
N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2£-2-propenamide, or a pharmaceutically acceptable salt thereof, are important compounds of fomiula le.
The present invention further relates to the compounds of the formula If

or a phamiaceutically acceptable salt thereof. The variable substituents are as defined above.
Useful compounds of formula If are those wherein R2 is H, or -(CH2)pCH2OH, wherein p is 1-3, especially those wherein R1 is H; such as those wherein R1 is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
N-hydroxy-3-[4-[[[2-(benzofur-3-yl)"ethyl]-amino]methyl]phenyl]-2E-2-propenamide,or a pharmaceutically acceptable salt thereof, is an important compound of formula If.
The compounds described above are often used in the form of a pharmaceutically acceptable salt. Phamiaceutically acceptable salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts. Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate. Examples of metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of ammonium salts are ammonium salt and tetramethylammonium salt. Examples of organic amine addition salts are salts with morpholine and piperidine. Examples of amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine. Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts.
As is evident to those skilled in the art, the many of the deacetylase inhibitor compounds of the present invention contain asymmetric carbon atoms. It should be understood, therefore, that the individual stereoisomers are contemplated as being included within the scope of this invention.
The hydroxamate compounds of the present invention can be produced by known organic synthesis methods. For example, the hydroxamate compounds can be produced

by reacting methyl 4-formyl cinnamate with tryptamine and then converting the reactant to the hydroxamate compounds. As an example, methyl 4-formyl cinnamate 2, is prepared by acid catalyzed esterification of 4-formylcinnamic acid 3 (Bull. Chem. Soc. Jpn. 1995; 68:2355-2362). An altemate preparation of methyl 4-formyl cinnamate 2 is by a Pd-catalyzed coupling of methyl acrylate 4 with 4-bromobenzaldehyde 5.

Additional starting materials can be prepared from 4-carboxybenzaldehyde 6, and an exemplary method is illustrated for the preparation of aldehyde 9. shown below. The carboxylic acid in 4-carboxybenzaldehyde 6 can be protected as a silyl ester (e.g., the f-butyldimethylsilyl ester) by treatment with a silyl chloride (e.g., f-butyldimethylsilyl chloride) and a base (e.g. triethylamine) in an appropriate solvent (e.g., dichloromethane). The resulting silyl ester 7 can undergo an olefination reaction (e.g., a Horner-Emmons olefination) with a phosphonate ester (e.g., triethyl 2-phosphonopropionate) in the presence of a base (e.g., sodium hydride) In an appropriate solvent (e.g., tetrahydrofuran (THF)). Treatment of the resulting diester with acid (e.g., aqueous hydrochloric acid) results in the hydrolysis of the silyl ester providing acid 8. Selective reduction of the carboxylic acid of 8 using, for example, borane-dimethylsuflide complex in a solvent (e.g., THF) provides an intermediate alcohol. This intermediate alcohol could be oxidized to aldehyde 9 by a number of known methods, including, but not limited to, Swern oxidation, Dess-Martin periodinane oxidation, Moffatt oxidation and the like.

The aldehyde starting materials 2 or 9 can be reductively aminated to provide secondary or tertiary amines. This is illustrated by the reaction of methyl 4-formyl cinnamate 2 with tryptamine 10 using sodium triacetoxyborohydride (NaBH(0Ac)3) as the reducing agent in dichloroethane (DCE) as solvent to provide amine 11. Other reducing agents can be used, e.g.. sodium borohydride (NaBH4) and sodium cyanoborohydride (NaBH3CN), in other solvents or solvent mixtures in the presence or absence of acid catalysts (e.g., acetic acid and trifluoroacetic acid). Amine 11 can be converted directly to hydroxamic acid 12 by treatment with 50% aqueous hydroxylamine in a suitable solvent (e.g., THF in the presence of a base, e.g., NaOH). Other methods of hydroxamate fomiation are known and include reaction of an ester with hydroxylamine hydrochloride and a base (e.g., sodium hydroxide or sodium methoxide) in a suitable solvent or solvent mixture (e.g., methanol, ethanol or methanol/THF).

Aldehyde 2 can be reductively aminated with a variety of amines, exemplified by, but not limited to. those illustrated in Table 1. The resulting esters can be converted to target hydroxamates by the methods listed.
Table 1

An alternate synthesis of the compounds of this invention starts by reductive amination of 4-formyl cinnamic acid 3, illustrated below with 3-phenylpropylamine 13, using, for example, NaBHgCN as the reducing agent in MeOH and HOAc as a catalyst. The basic nitrogen of the resulting amino acid 14 can be protected, for example, as f-butoxycarbamate (BOC) by reaction with di--t- butyldicarbonate to give 15.

The carboxylic acid can be coupled with a protected hydroxylamine (e.g., Otrityl hydroxylamine) using a dehydrating agent (e.g., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI)) and a catalyst (e.g., 1-hydroxybenzotriazole hydrate (HOBT)) in a suitable solvent (e.g., DMF) to produce 16. Treatment of 16 with a strong acid (e.g., trifluoroacetic acid (TFA)) provides a hydroxamic acid 17 of the present invention. Additional examples of compounds that can be prepared by this method are:

Tertiary amine compounds can be prepared by a number of methods. Reductive amination of 30 with nicotinaldehyde 32 using NaBHaCN as the reducing agent in dichloroethane and HOAc as a catalyst provides ester 34. Other reducing agents can be used (e.g., NaBH4 and NaBH(0Ac)3) in other solvents or solvent mixtures in the presence or absence of acid catalysts (e.g., acetic acid, trifluoroacetic acid and the like). Reaction of ester 34 with HONH2.HCI. NaOH in MeOH provides hydroxamate 36.

Tertiary amine compounds prepared by this methodology are exemplified, but not limited to, those listed in Table 2.

An alternate method for preparing tertiary amines Is by reacting a secondary amine with an alkylating agent in a suitable solvent in the presence of a base. For example, heating a dimethylsulfoxide (DMSO) solution of amine 11 and bromide 40 in the presence of (j-Pr)2NEt yielded tertiary amine 42. Reaction of the tertiary amine 42 with HONH2.HCI, NaOH in MeOH provides hydroxamate 43. The silyl group can be removed by any method

known to those skilled in the art. For example, the hydroxamate 43 can be treated with an acid, e.g., trifluoroacetic acid, or fluoride to produce hydroxyethyl compound 44.

The hydroxamate compound, or salt thereof, is suitable for preparing pharmaceutical compositions, especially pharmaceutical compositions having deacetylase, especially histone deacetylase, inhibiting properties. Studies with athymic mice demonstrate that the hydroxamate compound causes HDA inhibition and increased histone acetylation in vivo, which triggers changes in gene expression that correlate with tumor growth inhibition.
The present invention further includes pharmaceutical compositions comprising a pharmaceulically effective amount of one or more of the above-described compounds as active ingredient. Pharmaceutical compositions according to the invention are suitable for enteral, such as oral or rectal, and parenteral administration to mammals, Including man, for the treatment of tumors, alone or in combination with one or more pharmaceutically acceptable carriers.
The hydroxamate compound is useful in the manufacture of pharmaceutical compositions having an effective amount the compound in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with (a) diluents; (b) lubricants, (c) binders (tablets); if desired, (d) disintegrants; and/or (e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants,

such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, the compositions may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain preferably about 1 to 50% of the active ingredient.
Suitable formulations also include formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may Include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
As discussed above, the compounds of the present invention are useful for treating proliferative diseases. A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance.
In a broader sense of the invention, a proliferative disease may furthemriore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis,

atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
The compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particulariy in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis. In addition, the hydroxamate compound induces p21, cyclin-CDK interacting protein, which induces either apoptosis or G1 arrest in a variety of cell lines.
The following examples are intended to illustrate the invention and are not to be construed as being limitations thereto.
Example P1
Preparation of A/-Hydroxy-3-[4-[[[2-(1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide.
4-fonTiylcinnamic acid methylester is produced by adding 4-formylcinnamic acid (25 g, 0.143 mol) in MeOH and HCI (6.7 g, 0.18 mol). The resulting suspension is heated to reflux for 3 hours, cooled and evaporated to dryness. The resulting yellow solid is dissolved in EtOAc, the solution washed with saturated NaHCO3, dried (MgSO4) and evaporated to give a pale yellow solid which is used without further purification (25.0 g, 92%). To a solution of tryptamine (16.3 g, 100 mmol) and 4-formylcinnamic acid methylester (19 g, 100 mmol) in dichloroethane, NaBH(0Ac)3 (21 g, 100 mmol) is added. After 4 hours the mixture is diluted with 10% K2CO3 solution, the organic phase separated and the aqueous solution extracted with CH2CI2. The combined organic extracts are dried (Na2SO4), evaporated and the residue purified by flash chromatography to produce 3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester (29 g). A solution of KOH (12.9 g 87%, 0.2 mol) In MeOH (100 mL) is added to a solution of HONH2HCI (13.9 g, 0.2 mol) in MeOH (200 mL) and a precipitate results. After 15 minutes the mixture is filtered, the filter cake

washed with MeOH and the filtrate evaporated under vacuum to approximately 75 mL. The mixture is filtered and the volume adjusted to 100 mL with MeOH. The resulting solution 2M HONH2 is stored under N2 at -20o C for up to 2 weeks. Then 3-(4-{[2-(1 Wndol-3-yl)-ethylamino]-methyl}-phenyl)-(2e)-2-propenoic acid methyl ester (2.20 g, 6.50 mmol) is added to 2 M HONH2 in MeOH (30 mL, 60 mmol) followed by a solution of KOH (420 mg, 6.5 mmol) in MeOH (5 mL). After 2 hours dry ice is added to the reaction and the mixture is evaporated to dryness. The residue is dissolved in hot MeOH (20 mL), cooled and stored at -20oC ovemight. The resulting suspension is filtered, the solids washed with ice cold MeOH and dried under vacuum, producing A/-Hydroxy-3-[4-[[[2-(1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (m/z 336 [MH_+]).
Example P2
Preparation of N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indoN3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide
A solution of 3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2£)-2-propenoic acid methyl ester (12.6 g, 37.7 mmol). (2-bromoethoxy)-tert-butyldimethylsilane (12.8 g, 53.6 mmol), (i-Pr)2NEt. (7.42 g, 57.4 mmol) in DMSO (100 mL) is heated to 50° 0. After 8 hours the mixture is partitioned with CH2CI2/H2O. The organic layer is dried (Na2SO4) and evaporated. The residue is chromatographed on silica gel to produce 3-[4-({[2-(tert-butyldimethylsilanyloxy)-ethyl]-[2-(1Wndol-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2E)-2-propenoic acid methyl ester (13.1 g). Following the procedure described for the preparation of the hydroxamate compound in Example PI, 3-[4-(([2-(tert-butyldimethylsilanyloxy)-ethyl]-[2-(1 W-indoI-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2E)-2-propenoic acid methyl ester (5.4 g. 11 mmol) is converted to N-hydroxy-3-[4-({[2-(tert-butyldimethylsilanyloxy)-ethyl]-[2-(1 H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2£)-2-propenamide (5.1 g,) and used without further purification. The hydroxamic acid (5.0 g, 13.3 mmol) is then dissolved in 95% TFA/H2O (59 mL) and heated to 40 - 50 °C for 4 hours. The mixture is evaporated and the residue purified by reverse phase HPLC to produce N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1/+indol-3-yl)-ethyll-amino]methyl]phenyl]-2E-2-propenamide as the trifluoroacetate salt (m/z 380 [MHI).

Example P3
Preparation of N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyI]phenyl]-2E'-2-propenamicle.
A suspension of LiIH4 (17 g, 445 mmol) in dry THF (1000 mL) is cooled to 0 ^C and 2-methylindole-3-glyoxylamide (30 g, 148 mmol) is added in portions over 30 min. The mixture is stirred at room temperature for 30 min. and then maintained at reflux for 3 h. The reaction is cooled to 0 °C and treated with H2O (17ml), 15% NaOH (aq., 17ml) and H2O (51ml), The mixture is treated with MgSO4, filtered and the filtrate evaporated to give 2-methyltryptamine which is dissolved in MeOH. Methyl 4-fonnylcinnamate (16.9 g, 88.8 mmol) is added to the solution, followed by NaBHsCN (8.4 g) and AcOH (1 equiv,). After 1h the reaction Is diluted with NaHCO2(aq.) and extracted with EtOAc. The organic extracts are dried (MgSO4), filtered and evaporated. The residue is purified by chromatography to give 3-(4-{[2-(2-methyl-1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester. The ester is dissolved In MeOH, 1.0 M HCI/dioxane (1-1.5 equiv.) is added followed by Et2O. The resulting precipitate is filtered and the solid washed with Et2O and dried thoroughly to gfve 3-(4-{[2-(2-methyl-1 H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester hydrochloride. 1,0 M NaOH (aq., 85 mL) is added to an ice cold solution of the methyl ester hydrochloride (14.9 g, 38.6 mmol) and HONH2 (50% aq. solution, 24.0 mL, ca. 391.2 mmol). After 6 h, the ice cold solution is diluted with H2O and NH4CI (aq., 0.86 M, 100 ml). The resulting precipitate is filtered, washed with H2O and dried to afford N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (m/z 350 [MH1).
Examples 1-265
The following compounds are prepared by methods analogous to those disclosed in Examples PI, P2 and P3:

The compounds of Examples 1-265 show an HDA enzyme IC50 in the range from about 0.005 to about 0.5 jiM.
Example B1
Cell lines H1299 (human lung carcinoma cell) and HCT116 (colon tumor cell) are obtained from the American Type Culture Collection, Rockville, MD. The cell lines are free of Mycoplasma contamination (Rapid Detection System by Gen-Probe, Inc., San Diego, CA) and viral contamination (MAP testing by MA BioServices, Inc., Rockville, MD). The cell lines are propagated and expanded in RPM11640 medium containing 10% heat-inactivated FBS (Life Technologies, Grand Island, NY). Cell expansions for implantation are perfomied in cell factories (NUNC, purchased from Fisher Scientific, Springfield, NJ). Cells are harvested at 50-90% confluency, washed once with HBSS (Hank's Balanced Salt Solution) containing 10% FBS, and suspended in 100% HBSS.
Cell proliferation is measured with a commercial MTS kit (Promega, Madision, Wis.) assay using an adaptation of published procedures, for example, that disclosed in Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Alley MC, et a!., Cancer Res. 1988; 48:589-601. Cells are plated in 96-well tissue culture dishes, with top and bottom rows left empty. H1299 and HCT116 cells

are suspended in complete media at a density of 5.3 x 103 and 3.6 x 10^ cell/mL, respectively, and 190 μl are added per well. Each cell line is added to one half of the plate. Complete medium (200 μL) is added to the top and bottom rows. Twenty-four hours later, 10 μl of MTS solution is added to one of the plates to determine the activity at the time of compound addition (To). The plate is incubated at 37oC for 4 hours and the OD490 is measured on a Molecular Devices Thermomax at 490 nm using the Softmax program. The To plate serves as a reference for initial activity at the beginning of the experiment.
Five serial dilutions (1:4) of each compound are made in a 96-deep well plate with the highest concentrations on the edge of plate. Two cell lines are tested with two compounds per plate. Ten microliters of each of the five dilutions are added in triplicate and complete medium alone is added to columns six and seven. The plates are incubated at 37 °C for 72 hours. The MTS solution is added (as for the To plate) and read four hours later.
In order to analyze the data, the average background value (media alone) is subtracted from each experimental well; the triplicate values are averaged for each compound dilution. The following formulas are used to calculate percent growth. If X > To. % Growth = ((X-To)/(GC -To)) x 100 If X in which To = (average value of cell viability at time 0) - background GC = average value of untreated cells (in triplicate) - background X = average value of compound treated cells (in triplicate) - background The **% Growth- is plotted against compound concentration and used to calculate IC50S employing the linear regression techniques between data points to predict the concentration of compounds at 50% inhibition.
Lactate salts of N-hydroxy-3-[4-[[[2-(1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD1), N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD2), N-hydroxy-3-[4-[[[2-(5-methoxy-1 H indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide(CMD3), N-hydroxy-3-[4-[[[2-(5-fluoro-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD4), N-hydroxy-3-[4-[[[2-(benzofur-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD5) having a purity of higher than 95% are dissolved in pure dimethylsulfoxide (DMSO) to create a stock solution. The stock solution is diluted with 5% dextrose injection, USP, Just prior to dosing. In addition, N-(2-aminophenyl)-4-[N-pyridin-3-yl)methoxycarbonylaminomethyl]benzamide is synthesized in accordance with Example 48 of EP 0 847 992 and used as a control compound (CMDC). Inhibition of cell growth in monolayer for 72 hours of compound treatment is measured in

triplicate experiments and used to derive the IC50 by MTS assay. The results are shown in Table B1.
Table B1

Compound
CMD1
CMD2
CMD3
CMD4
CMD5
CMDC

Monolaver Growth IC50 (μ.M)
H1299 HCT116
0.40 0.03
0.15 0.01
0.58 0.03
0.28 0.03
0.18 0.03
6.8 0.67

The results show that the hydroxamate compounds of the present invention are highly active in inhibition of tumor cell growth. In addition to the above results, it has been observed that the compounds selectively inhibited tumor cells while showing minimal inhibition activities in non-tumorous cells.
The cells treated with the hydroxamate compounds are also tested for the induction of p21 promoter, which is a key mediator of G1 arrest and differentiation. The hydroxamate compounds activate the p21 promoter to a readily detectable level at a concentration within two-fold of their respective IC50 for monolayer cell growth inhibition in H1299. Without being bound by any particular theory, the correlation appears to demonstrate that HDA inhibition leads to transcriptional activation of genes that inhibit tumor cell proliferation.
Example B2
HDA is partially purified from H1299, human non-small cell lung carcinoma cells (obtained from American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, USA). Cells are grown to 70-80% confluence in RPMI media in the presence of 10% FCS, harvested and lysed by sonication. The lysate is centrifuged at 23, 420g for 10-15 min, the supernatant is applied to a Hiload 26/10 High performance Q-sepharose column (Amersham Phamiacia Biotech), and equilibrated with a buffer containing 20 mM Tris

pH8.0,1 mM EDTA, 10 mM NH4CI2,1 mM p-Mercaptoethanol, 5% glycerol. 2 μg/mL aprotinin, 1 μg/mL leupeptin, and 400 mM PMSF. Proteins are eluted in 4mL aliquotes with a linear gradient from 0-500 mM NaCI in the above buffer at a flow rate of 2.5 mL/min. Each preparation of partially purified HDA enzyme is titrated to determine the optimal amount needed to obtain a signal to noise ratio of at least 5 to 1. Generally, 20-30 μl of partially purified HDA (5-10 mg protein/mL) is mixed with 2 μL of compound solution in DMSO in a deep well titer plate (Beckman). The compounds are serially diluted in DMSO to generate stocks at 20-fold of the assay concentrations. Final concentrations of compounds in the assay are 10μM, 2μM, 400 nM, 80 nM, and 16 nM with the final percentage of DMSO in each enzyme reaction equaling 0.1%. Each concentration of compound is assayed in duplicate. The substrate used in the reaction is a peptide of amino acid sequence, SGRGKGGKGLGKGGAKRHRKVLRD, corresponding to the twenty-four N-terminal amino acids of human histone H4, biotinylated at the N-terminus and penta-acetylated, at each lysine residue with 3H-acetate. To Initiate the reaction, the substrate Is diluted in 10 jiL of Buffer A (100 mM Tris pH 8.0, 2 mM EDTA). added to the enzyme mixture and collected at the bottom of the deep well plate by centrifugation for 5 minutes at 1500 rpm. Following centrifugation, the mixture is incubated at 37 °C for 1.5 hr. The reaction is stopped by the addition of 20 μL of the Stop Buffer (0.5N HCI, 0.08M Acetic Acid). At this point, the assay proceeds to the robotic extraction phase or is frozen for several days at -80 °C.
The extraction of enzymatically cleaved 3H-acetate groups from the reaction mixture is achieved with the solvent TBME (t-butyl methyl ether) using the Tomtec Quadra 96 workstation. A program is written to add 200 μL of TBME to a 96 -deep well- plate. The workstation is programmed to aspirate 50 μL of air followed by 200 μL of TBME and finally another 25 pL of air, which is dispensed into the each well of the plate. The contents of the deep well were mixed thoroughly by pipetting 160 μL up and down 10 times. Before addition of TBME to the reaction mixture, it is necessary to -pre-wef the pipette tips with TBME to prevent the solvent from dripping during the transfer to the deep well plate. The organic and aqueous phases in the deep well are separated by centrifugation at 1500 rpm for 5 min. Opti-Phase Supermix liquid scintillation cocktail (200 μL) (Wallac) is added to each well of the 96-well Trilux plate (Wallac). The deep well and Trilux plates are placed back on the workstation programmed to aspirate 25 pL of air into the pipette tips followed by 100 pL of the upper TBME phase and transfer It Into the Trilux plate. The solutions are mixed by pipetting and expelling 50 pL, five times, within the same well. The Trilux plate is

covered with clear film and read on a 1450 MicroBeta Trilux liquid scintillation and luminescence counter (Wallac) with a color/chemical quench and dpm correction.
In order to determine the IC50 values, the data are analyzed on a spreadsheet. The analysis requires a correction for the background luminescence that is accomplished by subtracting the dpm values of wells without 3H substrate from the experimental wells. The corrected dpm values along with the concentrations of the compounds are used to calculate IC50 using the user-defined spline function. This function utilizes linear regression techniques between data points to calculate the concentration of compounds that produced 50% inhibition. The results are shown in Table B2.

Table B2
ComDOund HDA Enzvme Activity 1055μM
CMD1 0.032
CMD2 0.063
CMD3 0.014
CMD4 0.014
CMD5 0.016
CMDC >10
Example 83
The A549 non-small cell lung human tumor cell line is purchased from the American Type Culture Collection, Rockville, MD. The cell line is free of Mycoplasma contamination (Rapid Detection System by Gen-Probe, Inc., San Diego, CA) and viral contamination (MAP testing by MA BioServices, Inc., Rockville, MD). The cell line is propagated and expanded in RPMI 1640 medium containing 10% heat-inactivated PBS (Life Technologies, Grand Island, NY). Cell expansions for implantation are performed in cell factories (NUNC, purchased from Fisher Scientific, Springfield, NJ). Cells are harvested at 50-90% confluency, washed once with HBSS containing 10% PBS, and suspended in 100% HBSS.
Outbred athymic (nu/nu) female mice (-Hsd:Athymic Nude-nu- from Marian Sprague Dawley, Indianapolis, IN) are anesthetized with Metofane (Mallinckrodt Veterinary, Inc.,

Mundelein, IL), and 100 μL of the cell suspension containing 1x107 cells is injected subcutaneously into the right axillary (lateral) region of each animal. Tumors are allowed to grow for about 20 days until a volume of -100 mm3 is achieved. At this point, mice bearing tumors with acceptable morphology and size are sorted into groups of eight for the study. The sorting process produces groups balanced with respect to mean and range of tumor size. Antitumor activity is expressed as % T/C, comparing differences in tumor volumes for treatment group (T) to vehicle control group (C). Regressions are calculated using the formula: (1-T/To) x 100%. where T is the tumor volume for the treatment group at the end of the experiment, and To is the tumor volume at the beginning of the experiment.
CMD1 is administered intravenously, once daily 5x/week for three weeks, at doses of 10, 25, 50, or 100 mg/kg. The final DMSO concentration is 10%. Each test group has eight mice. Tumors are measured, and individual animal body weights recorded. Table B3 shows the results on the 41st day.

Note:*1. Difference in mean tumor volume for a group of animals at the end of the experiment minus mean tumor volume at the beginning.
*2. Difference in body weight for a group of animals at the end of the experiment minus mean tumor volume at the beginning.
*3. Standard error of the mean.
*4.5% dextrose injection, USP.

Example B4
Example B3 repeated except CMD2 is used. Table B4 shows the results.

Example B5
Example B3 is repeated except the HCT116 colon tumor cell line is used in place of the A549 cell line. The HCT116 cell line Is also obtained from American Type Culture Collection, Rockviile, MD, and the cell line is free of Mycoplasma contamination and viral contamination. The results are recorded on the 34th day and are shown in Table 85.
Table B5

Example B6
Example B4 is repeated except the HCT116 colon tumor cell line is used in place of the A549 cell line. The HCT116 is also obtained from American Type Culture Collection, Rockville, MD. and the cell line is free of Mycoplasma contamination and viral contamination. The results are recorded on the 34*^ day and are shown in Table B6.

Annexin V binding was used as a marker for the early stages of apoptosis. A549, HCT116 and Normal Demrial Human Fibroblasts (NDHF) cells are treated separately with four compounds (CMD1, CMD2, CMD3 and CMD4) for 24 or 48 hours, stained with annexin V and compared to cells treated similarly with vehicle (DMSO). Cells are examined by fluorescence microscopy. Those undergoing apoptosis exhibit green fluorescent membrane staining. Viability is assessed by the counterstain, propidium iodide. Cells detected by red fluorescence are not viable. A small percentage of A549 and the majority of HCT116 cells exhibit cell surface staining with annexin V after 24 hour exposure to each of the four compounds. After 48 hour treatment, the majority of the A549 and HCT116 stain with annexin V and/or propidium iodide indicating that the compounds induce apoptotic cell death. In contrast, NDHF cells do not show noticeable annexin V staining after 24 hour exposure and limited annexin V staining with CMD3 after 48 hour. These data show that

NDHF cells predominantly underwent non-lethal growth arrest upon compound treatment, consistent with the cell cycle profile.
The staining results demonstrate that the hydroxamate compounds of the present invention cause tumor cells to die by apoptosis, while causing normal fibroblast to predominantly undergo cell cycle arrest, clearly demonstrating the selective efficacy of the present compounds.

What is claimed is:
1. A compound of the formula I

2. A compound of claim 1 wherein each of R1, X, Y, R3, and R4 is H.
3. A compound of ciaim 2 wherein one of n2 and n3 is zero and the other is 1,
4. A compound of claim 3 wherein R2 is H or-CH2-CH2-OH.
5. A compound of claim 1 of the formula la

or a pharmaceutically acceptable salt thereof.
6. A compound of claim 1 of the formula la

R5' is aryl, arylalkyi, an aromatic polycycle, a non-aromatic polycycle or a mixed aryl and non-aryl polycycle, or a pharmaceutically acceptable salt thereof.
7. A compound of claim 6 wherein R5' is aryl or arylalkyi.

8. A compound of claim 7 wherein R5' is p-fluorophenyl, p-chlorophenyl, p-O-C1-C4-alkylphenyl, p-C1-C4-alkylphenyl, benzyl, ortho, meta or para-fluorobenzyl. ortho, meta or para-chlorobenzyl, or ortho, meta or para - mono, di or tri-O-C1-C4-alkylbenzyl.

wherein
R2' is selected from H, C1-C6 alkyl, C4-C6 cycloalkyi, cycloalkylalkyi, -(CH2)2-4OR21 where R21 is H, methyl, ethyl, propyl, or isopropyl, and
R5" is unsubstituted or substituted 1 H-indol-3-yl, benzofuran-3-yl or quinolin-3-yl, or a pharmaceutically acceptable salt thereof.
10, A compound of claim 9 wherein R5" is substituted 1H indol-3-yl or substituted
benzofuran-3-yl.
11. A compound of claim 1 of the formula Ic

wherein
the ring containing Z1 is aromatic or non-aromatic which non-aromatic rings are saturated or unsaturated, Zi is O, S or N-R20;

or a pharmaceutically acceptable salt thereof.
12. A compound of claim 11 wherein Z^ is N-R20.
13. A compound of claim 11 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1.
14. A compound of claim 1 of the formula Id

15. A compound of claim 14 wherein R2 is H or-CH2-CH2-OH and the sum of q and r is 1.
16. A compound of claim 11 of the formula le

C-cycloalkyI, phenyl or heteroaryl.
18. A compound of claim 16 wherein R2 is H, or -(CH2)pCH2OH and wherein p is 1-3.
19. A compound of claim 18 wherein Ri is H and X and Y are each H, and wherein q is 1-3
and r is 0 or wherein q is 0 and r is 1 -3.

21. A compound of claim 20 wherein R2 is H, or -(CH2)pCH2OH.
22. A compound of claim 21 wherein p is 1-3.

23. A compound of claim 22 wherein R1 is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3.
24. A compound of claim 23 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1.

27. A compound of claim 26 which is N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
28. A compound of claim 11 of the formula If

or a pharmaceutically acceptable salt thereof.

or a pharmaceutically acceptable salt thereof.

34. A pharmaceutical composition of claim 33 wherein the compound of fomnula 1 is
selected from the group consisting of N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H"-ndol-3-
yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1HHndol-3-yl)ethyl]-
amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4"[[[2-(2"methyl-1H-indol-3-yl)-
ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a phannaceutically acceptable salt
thereof.
35. A phamiaceutical composition of claim 34 wherein the compound of formula I is N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a phamiaceutically acceptable salt thereof.
36. A phamiaceutical composition of claim 33 wherein the compound of formula I is N-hydroxy-3-[4-[[[2-(benzofur-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
37. A method for treating a proliferative disorder in a mammal which comprises administering to said mammal a compound of the formula I

together with the carbon to which it is bound can form a C4 - C9 heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring;

or a pharmaceutically acceptable salt thereof,

into the environment of a mammalian cell.
40. A method of claim 39 wherein the compound of formula I is selected from the group consisting of N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.

41. A compound substantially as herein described and exemplified.
42. A pharmaceutical composition substantially as herein described and exemplified.

Documents:

http://ipindiaonline.gov.in/patentsearch/GrantedSearch/viewdoc.aspx?id=nyrtsEPdZwwEp4EuWRdjfg==&loc=egcICQiyoj82NGgGrC5ChA==

« Previous Patent

Next Patent »

Patent Number

269467

Indian Patent Application Number

306/CHENP/2003

PG Journal Number

44/2015

Publication Date

30-Oct-2015

Grant Date

23-Oct-2015

Date of Filing

20-Feb-2003

Name of Patentee

NOVARTIS AG

Applicant Address

LICHTSTRASSE 35, CH-4056 BASEL, SWITZERLAND

Inventors:

#	Inventor's Name	Inventor's Address
1	BAIR, KENNETH, WALTER	95 MELROSE ROAD, MOUNTAIN LAKES, NJ 07046, USA
2	GREEN, MICHAEL, A	2180 BIDDLE LANE, EASTON, PA 18040 USA
3	PEREZ, LAWRENCE, B	12 WINDSOR PLACE, HACKETTSTOWN, NJ 07840, USA
4	REMISZEWSKI, STACY, W	147 HONEYSUCKLE DRIVE, WASHINGTON TOWHSHIP, NJ 07676 USA
5	SAMBUCETTI, LIDIA	32 LONE MOUNTAIN COURT, PACIFICA, CA 94044, USA
6	VERSACE, RICHARD, WILLIAM	69 TOWNSEND ROAD, WANAQUE, NJ 07465 USA
7	SHARMA, SUSHIL, KUMAR	9 BARKLEY TERRACE, WEST ORANGE, NJ 07052 USA

PCT International Classification Number

C07D 209/16

PCT International Application Number

PCT/EP01/10037

PCT International Filing date

2001-08-30

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	60/229,943	2000-09-01	U.S.A.
2	60/292,232	2001-05-18	U.S.A.